243 related articles for article (PubMed ID: 18355043)
1. Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity.
Bender RP; Jablonksy MJ; Shadid M; Romaine I; Dunlap N; Anklin C; Graves DE; Osheroff N
Biochemistry; 2008 Apr; 47(15):4501-9. PubMed ID: 18355043
[TBL] [Abstract][Full Text] [Related]
2. Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIα: potential interactions with DNA in the ternary enzyme--drug--DNA complex.
Pitts SL; Jablonksy MJ; Duca M; Dauzonne D; Monneret C; Arimondo PB; Anklin C; Graves DE; Osheroff N
Biochemistry; 2011 Jun; 50(22):5058-66. PubMed ID: 21548574
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme.
Wilstermann AM; Bender RP; Godfrey M; Choi S; Anklin C; Berkowitz DB; Osheroff N; Graves DE
Biochemistry; 2007 Jul; 46(28):8217-25. PubMed ID: 17580961
[TBL] [Abstract][Full Text] [Related]
4. Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage.
Gentry AC; Pitts SL; Jablonsky MJ; Bailly C; Graves DE; Osheroff N
Biochemistry; 2011 Apr; 50(15):3240-9. PubMed ID: 21413765
[TBL] [Abstract][Full Text] [Related]
5. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N
Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388
[TBL] [Abstract][Full Text] [Related]
6. Two-Mechanism Model for the Interaction of Etoposide Quinone with Topoisomerase IIα.
Gibson EG; King MM; Mercer SL; Deweese JE
Chem Res Toxicol; 2016 Sep; 29(9):1541-8. PubMed ID: 27533850
[TBL] [Abstract][Full Text] [Related]
7. Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme.
Dickey JS; Osheroff N
Biochemistry; 2005 Aug; 44(34):11546-54. PubMed ID: 16114891
[TBL] [Abstract][Full Text] [Related]
8. Catalytic core of human topoisomerase IIα: insights into enzyme-DNA interactions and drug mechanism.
Lindsey RH; Pendleton M; Ashley RE; Mercer SL; Deweese JE; Osheroff N
Biochemistry; 2014 Oct; 53(41):6595-602. PubMed ID: 25280269
[TBL] [Abstract][Full Text] [Related]
9. Mutation of cysteine residue 455 to alanine in human topoisomerase IIalpha confers hypersensitivity to quinones: enhancing DNA scission by closing the N-terminal protein gate.
Bender RP; Osheroff N
Chem Res Toxicol; 2007 Jun; 20(6):975-81. PubMed ID: 17516663
[TBL] [Abstract][Full Text] [Related]
10. Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ.
Oviatt AA; Kuriappan JA; Minniti E; Vann KR; Onuorah P; Minarini A; De Vivo M; Osheroff N
Bioorg Med Chem Lett; 2018 Sep; 28(17):2961-2968. PubMed ID: 30006062
[TBL] [Abstract][Full Text] [Related]
11. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
[TBL] [Abstract][Full Text] [Related]
12. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
[TBL] [Abstract][Full Text] [Related]
13. Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha.
Vilain N; Tsai-Pflugfelder M; Benoit A; Gasser SM; Leroy D
Nucleic Acids Res; 2003 Oct; 31(19):5714-22. PubMed ID: 14500835
[TBL] [Abstract][Full Text] [Related]
14. The binding modes and binding affinities of epipodophyllotoxin derivatives with human topoisomerase IIα.
Naik PK; Dubey A; Soni K; Kumar R; Singh H
J Mol Graph Model; 2010 Dec; 29(4):546-64. PubMed ID: 21075653
[TBL] [Abstract][Full Text] [Related]
15. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
16. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
17. A two-drug model for etoposide action against human topoisomerase IIalpha.
Bromberg KD; Burgin AB; Osheroff N
J Biol Chem; 2003 Feb; 278(9):7406-12. PubMed ID: 12473657
[TBL] [Abstract][Full Text] [Related]
18. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
[TBL] [Abstract][Full Text] [Related]
20. Benzene metabolites antagonize etoposide-stabilized cleavable complexes of DNA topoisomerase IIalpha.
Baker RK; Kurz EU; Pyatt DW; Irons RD; Kroll DJ
Blood; 2001 Aug; 98(3):830-3. PubMed ID: 11468185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
